Hospital Infections: High Mortality for Bloodstream, Respiratory Cases

A recent multinational study published in EMJ (European Medical Journal) highlights that certain hospital-acquired infections (HAIs) are associated with markedly lower patient survival rates. The Comprehensive Online Database for Antimicrobial Resistance (CODAR) pilot study, a retrospective surveillance effort, analyzed data from 21 hospitals across five countries: India, Mexico, Saudi Arabia, Spain, and the United Kingdom. Covering the period from February 2023 to February 2024, the study included 7,434 patient records to provide a snapshot of infection types, pathogen distribution, antimicrobial treatment patterns, and clinical outcomes among hospitalized patients. The findings indicated that while urinary tract infections (UTIs) were the most common type of infection across the participating countries, accounting for 29.0% of cases, predominantly in female patients (59.0%), survival rates varied significantly by infection site. Patients with skin and skin structure infections exhibited the highest survival rate at 94.4% and the shortest mean hospital stay of 20.6 days. Conversely, lower survival rates were observed among patients diagnosed with bloodstream infections (81.7%), mixed infections (82.1%), and lower respiratory tract infections (83.3%). The study also noted variations in antimicrobial treatment patterns by country and infection type, with Meropenem being commonly used in India for most infection types, while amoxicillin clavulanate was prevalent in the UK. This study's findings corroborate extensive global research on the devastating impact of Healthcare-Associated Infections, also known as nosocomial infections. HAIs are infections acquired by patients during their stay in a healthcare facility and were not present or incubating at the time of admission. They pose a significant global public health concern, contributing substantially to increased morbidity, mortality, prolonged hospital stays, and escalating healthcare costs. Globally, approximately 1 in 10 patients is affected by HAIs, with this frequency being considerably higher in low- and middle-income countries (LMICs) and among high-risk patients, such as those in intensive care units (ICUs). For instance, in LMICs, the HAI rate can be twice that of high-income countries, reaching up to 15% of patients in acute-care hospitals. Common types of HAIs, beyond those specifically highlighted by the EMJ study, include surgical site infections (SSIs), catheter-associated urinary tract infections (CAUTIs), and ventilator-associated pneumonia (VAP), with pneumonia often cited as the most frequent and deadly HAI. Bloodstream infections and pneumonia, which showed lower survival in the EMJ study, are consistently identified as HAIs with particularly high mortality rates across various studies. Bloodstream infections can have crude mortality rates as high as 24% overall, with nosocomial bloodstream infections leading to significantly higher mortality (34%) compared to community-onset infections (14%). Ventilator-associated pneumonia has reported mortality rates ranging from 30% to 70%. The occurrence of HAIs can increase the risk of mortality by a factor of 1.5, with this risk being especially elevated for bloodstream infections and pneumonia. The burden of HAIs is particularly pronounced in countries like India, which was part of the CODAR study. India is estimated to bear a significant portion of the global burden of hospital-associated drug-resistant infections (HARIs), with approximately 9 million cases annually. Overall, HAIs account for an estimated 2 million cases and about 80,000 deaths annually in India. Factors contributing to this high burden include overcrowded hospitals, inadequate infrastructure, insufficient hygiene practices, a low healthcare professional-to-patient ratio, inappropriate use of invasive devices and antibiotics, and lax enforcement of regulations. HAIs also lead to substantially prolonged hospital stays in India, with an average increase of nearly 12 days for infected patients, resulting in significantly higher treatment costs—potentially two to four times more than for non-infected patients. Antimicrobial resistance (AMR) further compounds the challenge, as many HAIs are caused by drug-resistant bacterial pathogens, leading to higher mortality among infected patients. Globally, more than 5 million deaths were estimated to be associated with antimicrobial resistance in 2019, with healthcare-associated infections forming a major part of this figure. The COVID-19 pandemic also exacerbated HAI rates and AMR, emphasizing the need for robust infection prevention and control (IPC) programs. Effective prevention strategies are critical to mitigate the impact of HAIs. These include strict adherence to hand hygiene protocols, maintaining a clean and hygienic hospital environment, implementing antibiotic stewardship programs, screening and cohorting patients, proper use of personal protective equipment (PPE), and continuous staff education. Efforts to build an organizational culture of safety, engage leadership, and involve patients and families in prevention measures are also vital. The findings from the EMJ study and other research underscore the urgent need for ongoing surveillance, strengthened IPC practices, and collaborative global and national efforts to enhance patient safety and reduce the mortality and economic burden associated with hospital-acquired infections, especially in susceptible populations and resource-limited settings like India.

Frequently Asked Questions

Read Full Story on Quick Digest